Low level ALK FISH positive results should be approached with caution and confirmed by an orthogonal method.
作者信息
Toruner Gokce A
机构信息
Department of Hematopathology, Section of Cytogenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Transl Lung Cancer Res. 2023 Jul 31;12(7):1361-1363. doi: 10.21037/tlcr-23-265. Epub 2023 Jun 26.
Abstract
摘要
相似文献
1
Low level ALK FISH positive results should be approached with caution and confirmed by an orthogonal method.低水平ALK FISH阳性结果应谨慎对待，并通过正交方法进行确认。
Transl Lung Cancer Res. 2023 Jul 31;12(7):1361-1363. doi: 10.21037/tlcr-23-265. Epub 2023 Jun 26.
2
Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.非小细胞肺癌（NSCLC）中间变性淋巴瘤激酶（ALK）基因重排：多中心 ALK 检测结果。
Lung Cancer. 2013 Aug;81(2):200-6. doi: 10.1016/j.lungcan.2013.04.015. Epub 2013 May 10.
3
Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.非小细胞肺癌中间变性淋巴瘤激酶基因重排的异质性：小活检与切除标本的比较研究。
J Thorac Oncol. 2015 May;10(5):800-805. doi: 10.1097/JTO.0000000000000507.
4
Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.晚期非小细胞肺癌患者恶性胸腔积液细胞块中ALK重排的检测：Ventana免疫组织化学与荧光原位杂交的比较
Cancer Cytopathol. 2015 Feb;123(2):117-22. doi: 10.1002/cncy.21510. Epub 2014 Dec 19.
5
Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan.约旦非小细胞肺癌患者中的间变性淋巴瘤激酶重排。
J Int Med Res. 2022 Jun;50(6):3000605221104181. doi: 10.1177/03000605221104181.
6
RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.基于 RNA 的分析在免疫组化/荧光原位杂交结果不一致的非小细胞肺癌病例中检测 ALK 融合。
BMC Cancer. 2018 Nov 22;18(1):1158. doi: 10.1186/s12885-018-5070-6.
7
The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells.三维 DNA 荧光原位杂交（3D DNA FISH）在非小细胞肺癌（NSCLC）循环肿瘤细胞中检测间变性淋巴瘤激酶（ALK）的应用。
Cells. 2020 Jun 15;9(6):1465. doi: 10.3390/cells9061465.
8
Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.多色荧光原位杂交检测肺癌细胞学样本中间变性淋巴瘤激酶和 ROS 原癌基因 1 受体酪氨酸激酶重排。
J Clin Pathol. 2020 Feb;73(2):96-101. doi: 10.1136/jclinpath-2019-206152. Epub 2019 Sep 27.
9
Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer.印度非小细胞肺癌患者间变性淋巴瘤激酶重排的荧光原位杂交与免疫组织化学分析的不一致性
South Asian J Cancer. 2020 Jun;9(2):109-114. doi: 10.1055/s-0040-1721191. Epub 2020 Dec 14.
10
Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.克唑替尼治疗的非小细胞肺癌患者组织中间变性淋巴瘤激酶蛋白表达的定量分析
Clin Chem. 2016 Jan;62(1):252-61. doi: 10.1373/clinchem.2015.245860. Epub 2015 Nov 19.
本文引用的文献
1
False positivity in break apart fluorescence in-situ hybridization due to polyploidy.多倍体导致的分裂荧光原位杂交假阳性。
Transl Lung Cancer Res. 2023 Apr 28;12(4):676-688. doi: 10.21037/tlcr-22-516. Epub 2023 Apr 18.
2
ALK-positive lung cancer: a moving target.ALK 阳性肺癌：一个移动的目标。
Nat Cancer. 2023 Mar;4(3):330-343. doi: 10.1038/s43018-023-00515-0. Epub 2023 Feb 16.
3
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).ALK 阳性细胞的百分比和一线阿来替尼治疗晚期非小细胞肺癌的疗效：是否为新的分层因素？（土耳其肿瘤学组研究）。
J Cancer Res Clin Oncol. 2023 Jul;149(8):4141-4148. doi: 10.1007/s00432-022-04252-2. Epub 2022 Sep 1.
4
Catalog of 5' Fusion Partners in -positive NSCLC Circa 2020.2020年左右阳性非小细胞肺癌中5'融合伙伴目录
JTO Clin Res Rep. 2020 Feb 19;1(1):100015. doi: 10.1016/j.jtocrr.2020.100015. eCollection 2020 Mar.
5
Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors.低ALK FISH阳性的转移性非小细胞肺癌（NSCLC）患者在接受ALK抑制剂治疗后的无进展生存期较短。
Cancer Genet. 2020 Feb;241:57-60. doi: 10.1016/j.cancergen.2019.12.003. Epub 2019 Dec 13.
6
Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase () Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.荧光原位杂交 (FISH) 检测肺癌中间变性淋巴瘤激酶 () 重排：临床相关的技术方面。
Int J Mol Sci. 2019 Aug 13;20(16):3939. doi: 10.3390/ijms20163939.
7
ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer.ALK 重排：非小细胞肺癌的生物学、检测和治疗机会。
Crit Rev Oncol Hematol. 2019 Apr;136:48-55. doi: 10.1016/j.critrevonc.2019.02.006. Epub 2019 Feb 16.
8
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.布加替尼与克唑替尼用于治疗间变性淋巴瘤激酶阳性的非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.
9
Genome doubling shapes the evolution and prognosis of advanced cancers.基因组加倍塑造了晚期癌症的进化和预后。
Nat Genet. 2018 Aug;50(8):1189-1195. doi: 10.1038/s41588-018-0165-1. Epub 2018 Jul 16.
10
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.在三项针对 ALK 阳性非小细胞肺癌患者的前瞻性研究中，ALK FISH 阳性程度与克唑替尼疗效的相关性。
Ann Oncol. 2018 Sep 1;29(9):1964-1971. doi: 10.1093/annonc/mdy242.
Zotero 插件